Breast Cancer

The combination of ruxolitinib and trastuzumab without chemotherapy was well tolerated but failed to demonstrate improved progression-free survival compared with historical controls in patients with HER2+ metastatic breast cancer. Read Article ›

Results of the phase 3 HER2CLIMB study show that in patients with HER2+ metastatic breast cancer with and without brain metastases, the combination of tucatinib with capecitabine and trastuzumab significantly improves survival and could become a new standard of care. Read Article ›

Preclinical data demonstrated that tucatinib potentiates the activity of T-DM1 in HER2+ breast cancer models in vitro and in vivo, and enhances the activity of a camptothecin-based HER2 antibody-drug conjugate comprised of trastuzumab conjugated with 8 exatecan moieties. Read Article ›

Shanu Modi, MD, provided an overview of promising novel therapies in development for the treatment of refractory HER2+ metastatic breast cancer. Read Article ›

Results from the phase 2 PATRICIA study suggest pertuzumab plus high-dose trastuzumab may have clinical utility in some patients with HER2+ metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases. Read Article ›

Results from the MetaPHER study showed the safety profile of first-line subcutaneous trastuzumab + intravenous (IV) pertuzumab and IV docetaxel for HER2+ advanced breast cancer was consistent with the known safety profile and efficacy data reported for IV trastuzumab + IV pertuzumab and IV docetaxel. Read Article ›

The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer. Read Article ›

The addition of the cyclin-dependent kinase (CDK)4/CDK6 inhibitor ribociclib to standard endocrine therapy significantly extended overall survival (OS) compared with endocrine therapy alone in premenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results of the phase 3 MONALEESA-7 clinical trial, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Read Article ›

Two human genes, BRCA1 and BRCA2 (BRCA1/2), produce proteins that block the growth of cancer, such as breast or ovarian cancer. These proteins ensure the stability of each cell’s genetic material and help to repair damaged DNA. A mutation in either BRCA results in these proteins not functioning correctly. Specifically, DNA damage may not be repaired effectively, which can lead to cancer. Read Article ›

Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are expanding. The updated National Comprehensive Cancer Network (NCCN) guideline (version 1.2019) for the management of invasive breast cancer is focused on HR-positive, HER2-­negative disease. William J. Gradishar, MD, Director, Maggie Daley Center for Women’s Cancer Care, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, discussed the updated guideline at the NCCN 2019 Conference. Read Article ›

Want more Breast Cancer-related news?

Sign up for the OPM weekly e-Newsletter!

Enter your contact information below to recieve weekly oncology news & updates.

Page 7 of 12

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: